ImmunoGen, Inc.
IMGN
Classificação em ações
#2920
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Preço da ação
$31.23
Última sincronização: 2024-02-13
Valor de mercado
$6.24B
Variação (1 dia)
0.00%
Variação (1 ano)
-0.03%
País
US
Negociar ImmunoGen, Inc. (IMGN)
Categoria
Healthcare
Histórico de preços das ações de ImmunoGen, Inc. (IMGN)
Preço de fecho mais alto: $29.96 em 2024-02-01
Preço de fecho mais baixo: $3.94 em 2023-02-01
Preço de fecho mais baixo: $3.94 em 2023-02-01
Histórico de preços das ações da ImmunoGen, Inc. de 2023 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2024 | 1.66% |
| 2023 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
